Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for VSTM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 16.25M
March 31, 2026 -16.02M
December 31, 2025 -1.345M
September 30, 2025 -8.279M
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.00
September 30, 2024 0.00
June 30, 2024 28.99M
March 31, 2024 30.98M
December 31, 2023 12.44M
September 30, 2023 -70.08M
June 30, 2023 14.00M
March 31, 2023 -0.804M
December 31, 2022 13.02M
September 30, 2022 4.647M
June 30, 2022 29.25M
March 31, 2022 19.26M
December 31, 2021 0.066M
September 30, 2021 10.00M
June 30, 2021 2.393M
March 31, 2021 -12.37M
December 31, 2020 -79.38M
September 30, 2020 -0.006M
June 30, 2020 -0.027M
Date Value
March 31, 2020 32.05M
December 31, 2019 25.13M
September 30, 2019 17.59M
June 30, 2019 46.53M
March 31, 2019 0.363M
December 31, 2018 -126.80M
September 30, 2018 -15.48M
June 30, 2018 -0.53M
March 31, 2018 4.435M
December 31, 2017 4.509M
September 30, 2017 21.32M
June 30, 2017 14.02M
March 31, 2017 4.096M
December 31, 2016 1.027M
September 30, 2016 3.729M
June 30, 2016 31.11M
March 31, 2016 1.104M
December 31, 2015 15.19M
September 30, 2015 -3.791M
June 30, 2015 8.942M
March 31, 2015 -47.40M
December 31, 2014 13.48M
September 30, 2014 7.62M
June 30, 2014 17.92M
March 31, 2014 4.118M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Dianthus Therapeutics, Inc. -478.52M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M
Savara, Inc. 32.60M